{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:18:28Z","timestamp":1793114308380,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01-MH-116695"],"award-info":[{"award-number":["R01-MH-116695"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008374","name":"Emory Center for AIDS Research","doi-asserted-by":"crossref","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100008374","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1\/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of this trial was to determine safety and efficacy of ruxolitinib for PWH on antiretroviral therapy (ART).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>AIDS Clinical Trials Group (ACTG) A5336 was an open-label, multisite, randomized controlled trial (RCT). Participants were randomly assigned (2:1) using centralized software to ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks vs ART alone, stratified by efavirenz use. Eligible participants were suppressed on ART for \u22652 years, without comorbidities, and had &amp;gt;350 CD4+ T cells\/\u00b5L. Primary endpoints were premature discontinuation, safety events, and change in plasma interleukin 6 (IL-6). Secondary endpoints included other measures of inflammation\/immune activation and HIV reservoir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty participants were enrolled from 16 May 2016 to 10 January 2018. Primary safety events occurred in 2.5% (1 participant) for ruxolitinib and 0% for controls (P\u2005=\u2005.67). Three participants (7.5%) prematurely discontinued ruxolitinib. By week 5, differences in IL-6 (mean fold change [FC], 0.93 vs 1.10; P\u2005=\u2005.18) and soluble CD14 (mean FC, 0.96 vs 1.08; relative FC, 0.96 [90% confidence interval {CI}, .90\u20131.02]) levels for ruxolitinib vs controls was observed. Ruxolitinib reduced CD4+ T cells expressing HLA-DR\/CD38 (mean difference, \u20130.34% [90% CI, \u2013.66% to \u2013.12%]) and Bcl-2 (mean difference, \u20133.30% [90% CI, \u20134.72% to \u20131.87%]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this RCT of healthy, virologically suppressed PWH on ART, ruxolitinib was well-tolerated. Baseline IL-6 levels were normal and showed no significant reduction. Ruxolitinib significantly decreased markers of immune activation and cell survival. Future studies of Jak inhibitors should target PWH with residual inflammation despite suppressive ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02475655.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab212","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T04:14:35Z","timestamp":1614831275000},"page":"95-104","source":"Crossref","is-referenced-by-count":61,"title":["Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus"],"prefix":"10.1093","volume":"74","author":[{"given":"Vincent C","family":"Marconi","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Emory University Rollins School of Public Health, Atlanta, Georgia, USA"},{"name":"Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA"},{"name":"Emory Vaccine Center, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlee","family":"Moser","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gavegnano","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"Deeks","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M","family":"Lederman","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar T","family":"Overton","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athe","family":"Tsibris","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"Hunt","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kantor","sequence":"additional","affiliation":[{"name":"Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafick-Pierre","family":"Sekaly","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Tressler","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwyn J","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Moisi","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clagett","sequence":"additional","affiliation":[{"name":"Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R","family":"Hardin","sequence":"additional","affiliation":[{"name":"Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"del Rio","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"},{"name":"Emory University Rollins School of Public Health, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J","family":"Lennox","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"key":"2022011123270038500_CIT0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"T Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"2022011123270038500_CIT0002","doi-asserted-by":"crossref","first-page":"2040620719870052","DOI":"10.1177\/2040620719870052","article-title":"Updates in the management of polycythemia vera and essential thrombocythemia","volume":"10","author":"Bose","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2022011123270038500_CIT0003","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1346-8138.14986","article-title":"Janus kinase inhibitors: an innovative treatment for alopecia areata","volume":"46","author":"Park","year":"2019","journal-title":"J Dermatol"},{"key":"2022011123270038500_CIT0004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-019-00527-7","article-title":"The rationale for immunotherapy in myeloproliferative neoplasms","volume":"14","author":"Masarova","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"2022011123270038500_CIT0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000001014","article-title":"Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022011123270038500_CIT0006","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.atherosclerosis.2009.05.001","article-title":"Lipoprotein particle subclasses, cardiovascular disease and HIV infection","volume":"207","author":"Duprez","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022011123270038500_CIT0007","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/QAD.0b013e32835f6b0c","article-title":"Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers","volume":"27","author":"Borges","year":"2013","journal-title":"AIDS"},{"key":"2022011123270038500_CIT0008","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/dc10-0633","article-title":"Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy","volume":"33","author":"Brown","year":"2010","journal-title":"Diabetes Care"},{"key":"2022011123270038500_CIT0009","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QAI.0b013e3181e66216","article-title":"Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort","volume":"55","author":"Tien","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022011123270038500_CIT0010","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J Infect Dis"},{"key":"2022011123270038500_CIT0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.qai.0000437172.08127.0b","article-title":"Discordance between peripheral and colonic markers of inflammation during suppressive ART","volume":"65","author":"Dunham","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022011123270038500_CIT0012","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"2022011123270038500_CIT0013","doi-asserted-by":"crossref","first-page":"e1006740","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PLoS Pathog"},{"key":"2022011123270038500_CIT0014","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022011123270038500_CIT0015","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/JCM.02060-14","article-title":"Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy","volume":"52","author":"Cillo","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2022011123270038500_CIT0016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nprot.2008.108","article-title":"A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load","volume":"3","author":"Malnati","year":"2008","journal-title":"Nat Protoc"},{"key":"2022011123270038500_CIT0017","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"2022011123270038500_CIT0018","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2022011123270038500_CIT0019","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12185-020-02882-1","article-title":"Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection","volume":"112","author":"Galvez Acosta","year":"2020","journal-title":"Int J Hematol"},{"key":"2022011123270038500_CIT0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J Infect Dis"},{"key":"2022011123270038500_CIT0021","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"key":"2022011123270038500_CIT0022","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"key":"2022011123270038500_CIT0023","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"key":"2022011123270038500_CIT0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"key":"2022011123270038500_CIT0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-407707-2.00002-3","article-title":"Residual immune dysregulation syndrome in treated HIV infection","volume":"119","author":"Lederman","year":"2013","journal-title":"Adv Immunol"},{"key":"2022011123270038500_CIT0026","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jir060","article-title":"Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy","volume":"203","author":"Hunt","year":"2011","journal-title":"J Infect Dis"},{"key":"2022011123270038500_CIT0027","doi-asserted-by":"crossref","first-page":"e110731","DOI":"10.1371\/journal.pone.0110731","article-title":"CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells","volume":"9","author":"Cockerham","year":"2014","journal-title":"PLoS One"},{"key":"2022011123270038500_CIT0028","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J Virol"},{"key":"2022011123270038500_CIT0029","doi-asserted-by":"crossref","first-page":"e00012-17","DOI":"10.1128\/JVI.00012-17","article-title":"Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition","volume":"91","author":"Cummins","year":"2017","journal-title":"J Virol"},{"key":"2022011123270038500_CIT0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022011123270038500_CIT0031","article-title":"Use of baricitinib in patients with moderate and severe COVID-19","author":"Titanji","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022011123270038500_CIT0032","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab212\/41469107\/ciab212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/1\/95\/42107130\/ciab212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/1\/95\/42107130\/ciab212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T23:31:31Z","timestamp":1641943891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/1\/95\/6159796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,6]]},"published-print":{"date-parts":[[2022,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab212","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,6]]}}}